BTIG analyst Thomas Shrader reiterated a Buy rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Ovid Therapeutics Inc. (OVID) Reports Q2 EPS of $0.12August 13, 2024 8:13 AM Form 10-Q Ovid Therapeutics Inc. For: Jun 30August 13, 2024 8:04 AM Form 8-K Ovid Therapeutics Inc. For: Aug 13August 13, 2024 8:03 AM Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial ResultsAugust 13, 2024 8:00 AM